These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 22929407

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM.
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.
    Fang J, Bourin M, Baker GB.
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Feb; 359(2):147-51. PubMed ID: 10048600
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
    Hendset M, Molden E, Refsum H, Hermann M.
    J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
    [Abstract] [Full Text] [Related]

  • 30. Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo.
    Størset E, Bråten LS, Ingelman-Sundberg M, Johansson I, Molden E, Kringen MK.
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1531-1541. PubMed ID: 38963454
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ.
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.
    Remmerie BM, Sips LL, de Vries R, de Jong J, Schothuis AM, Hooijschuur EW, van de Merbel NC.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan 15; 783(2):461-72. PubMed ID: 12482489
    [Abstract] [Full Text] [Related]

  • 36. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
    Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E.
    Ther Drug Monit; 2016 Feb 15; 38(1):127-34. PubMed ID: 26418700
    [Abstract] [Full Text] [Related]

  • 37. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J.
    Int Clin Psychopharmacol; 2005 Mar 15; 20(2):71-8. PubMed ID: 15729081
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.